# Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

> **NCT02961816** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Palifermin
- **DRUG:** Panobinostat
- **DRUG:** Gemcitabine
- **DRUG:** Busulfan
- **DRUG:** Melphalan
- **DRUG:** Rituximab
- **DRUG:** Dexamethasone
- **DRUG:** Caphosol
- **DRUG:** Glutamine
- **OTHER:** Oral Cryotherapy (ice chips)
- **DRUG:** Pyridoxine
- **BIOLOGICAL:** Stem Cell Infusion
- **DRUG:** G-CSF

## Key facts

- **NCT ID:** NCT02961816
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-06
- **Primary completion:** 2021-06
- **Final completion:** 2021-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2017-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02961816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02961816, "Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02961816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*